Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349058 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL9005877 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL14401914 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13689098 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL8353738 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL14451045 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13305538 | 1.00 | HSD17B10 (0.37) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL4304713 | 0.88 | NR1H2 (0.34) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL4311042 | 0.88 | NR1H2 (0.34) | HSD17B10NR1H2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16843376 | 0.87 | NR1H2 (0.35) | HSD17B10NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209557-A | A peptoid compound with novel coronavirus main protease inhibitory activity and its preparation method | 潍坊中医药产业技术研究院 | 2023-12-12 | — | — | CN | claimed |
| US-12577240-B2 | Antiviral heteroaryl ketone derivatives | PFIZER INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12545671-B2 | Compound having biological activity such as antiviral activity | NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-2014648-A1 | PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885NR1H2 2620/4885SMN1; SMN2 3286/4885 |
| US-12545671-B2 | Compound having biological activity such as antiviral activity | SARS1, ACE2, ACE | HSD17B10 2602/4885NR1H2 543/4885SMN1; SMN2 1097/4885 |
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | C9, NPPA, ADH1C | HSD17B10 2530/4885NR1H2 4250/4885SMN1; SMN2 2825/4885 |
| US-12577240-B2 | Antiviral heteroaryl ketone derivatives | ACE2, SARS1, ACE | HSD17B10 525/4885NR1H2 270/4885SMN1; SMN2 1593/4885 |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | HSD17B10 1240/4885NR1H2 2901/4885SMN1; SMN2 3962/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | HSD17B10 3574/4885NR1H2 1773/4885SMN1; SMN2 1912/4885 |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | HSD17B10 3052/4885NR1H2 289/4885SMN1; SMN2 4813/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885NR1H2 2620/4885SMN1; SMN2 3286/4885 |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ACE, EIF2AK2 | HSD17B10 1647/4885NR1H2 3094/4885SMN1; SMN2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.